Estados financieros detallados de NovaBridge Biosciences (NBP): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.57, NBP presenta beneficios negativos (P/E no significativo) y un ROE del -1.45%. La capitalización bursátil es de $181M.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $11.3M | $53.8M | $30.0M | $1.54B | $88.0M | -$10.7M | $4.5M | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | $46.4M | 0 | 0 | 0 | 0 |
| Beneficio Bruto | $11.6M | $53.8M | $30.0M | $1.54B | $41.6M | -$10.7M | $4.5M | 0 | 0 |
| I+D | $267.1M | $426.0M | $840.4M | $984.7M | $190.3M | $155.5M | $114.4M | $158.9M | $9.0M |
| Generales y Administrativos | $25.4M | $66.4M | $654.6M | $402.4M | $899.9M | $199.9M | $63.9M | $216.5M | $4.5M |
| Gastos Operativos | $292.5M | $492.4M | $1.49B | $1.39B | $2.11B | $355.4M | $515.6M | $375.4M | $13.5M |
| Beneficio Operativo | -$273.9M | -$455.7M | -$1.46B | $155.6M | -$2.07B | -$366.1M | -$511.2M | -$375.4M | -$13.5M |
| EBITDA | -$279.3M | -$431.9M | -$197.3M | $168.3M | -$2.06B | -$356.4M | -$344.2M | -$373.5M | -$13.4M |
| Gastos por Intereses | $864338 | $1.7M | $427481 | $146480 | 0 | 0 | $101854 | 0 | 0 |
| Beneficio Antes de Impuestos | -$290.7M | -$416.8M | -$1.45B | $483.1M | -$2.33B | -$973.2M | -$1.47B | -$362.7M | -$12.6M |
| Impuestos | 0 | $1.7M | 0 | $12.2M | -$494814 | -$5.6M | -$1.26B | 0 | 0 |
| Beneficio Neto | -$298.2M | -$402.8M | -$1.45B | $470.9M | -$2.33B | -$967.5M | -$1.47B | -$162.3M | -$6.6M |
| BPA | $-5.13 | $-6.92 | $-25.53 | $8.07 | $-30.70 | $-30.38 | $-17.62 | $-4.46 | $-0.16 |
| BPA Diluido | $-5.13 | $-6.92 | $-25.53 | $6.90 | $-30.68 | $-30.38 | $-17.62 | $-4.46 | $-0.16 |
| Acciones en Circulación (Diluidas) | $58.2M | $58.2M | $58.2M | $68.4M | $76.0M | $82.5M | $83.2M | $81.2M | $41.6M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 |
| Beneficio Operativo | -$9.0M | -$10.4M | -$20.4M | -$20.3M |
| EBITDA | -$8.8M | -$10.4M | -$20.3M | -$20.3M |
| Beneficio Neto | -$6.8M | -$4.4M | -$18.9M | -$18.9M |
| BPA | $-0.16 | $-0.09 | $-0.16 | $-0.16 |
| BPA Diluido | $-0.16 | $-0.09 | $-0.16 | $-0.16 |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $307.9M | $1.59B | $1.14B | $4.76B | $552.8M | $3.21B | $291.5M | $498.2M | $30.1M |
| Inversiones a Corto | $266.2M | $256.0M | $32.0M | $31.5M | $118.2M | $235.4M | $20.2M | $767.4M | $30021 |
| Cuentas por Cobrar | $4.1M | $9.4M | $55.3M | $357.9M | $61.0M | $4.8M | $1.8M | 0 | $256327 |
| Inventario | 0 | 0 | -$55.9M | 0 | $4.3M | -$80.3M | 0 | 0 | 0 |
| Activos Corrientes | $691.6M | $2.04B | $1.36B | $5.34B | $750.2M | $3.63B | $329.9M | $1.29B | $31.1M |
| Inmovilizado Material | $22.3M | $27.7M | $46.5M | $40.3M | $24.9M | $124.0M | $5.6M | $27.7M | $421589 |
| Fondo de Comercio | $162.6M | $162.6M | $162.6M | $162.6M | $25.5M | $162.6M | 0 | 0 | 0 |
| Activos Intangibles | $148.8M | $148.8M | $148.8M | $120.4M | $18.8M | $118.9M | 0 | 0 | 0 |
| Activos Totales | $1.03B | $2.38B | $1.74B | $6.33B | $878.7M | $4.07B | $368.9M | $1.55B | $37.2M |
| Cuentas por Pagar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deuda a Corto | $99.0M | $80.0M | $50.0M | 0 | 0 | $2.7M | 0 | 0 | 0 |
| Pasivos Corrientes | $195.1M | $346.2M | $588.5M | $576.1M | $97.9M | $659.7M | $58.1M | $61.7M | $3.8M |
| Deuda a Largo | $114.0M | $67.0M | $68.2M | $5.5M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $1.33B | $3.33B | $3.77B | $712.2M | $163.4M | $1.07B | $126.3M | $84.1M | $4.2M |
| Reservas | -$357.9M | -$1.01B | -$2.49B | -$2.02B | -$683.2M | -$6.77B | -$1.26B | -$9.39B | -$190.5M |
| Patrimonio Neto | $410.5M | -$955.1M | $1.07B | $5.63B | $715.3M | $3.01B | $242.6M | $1.47B | $33.0M |
| Deuda Total | $213.0M | $147.0M | $132.5M | $19.1M | $17.6M | $38.3M | $3.9M | $28.3M | $438458 |
| Deuda Neta | -$361.2M | -$1.70B | -$1.04B | -$4.77B | -$653.3M | -$3.41B | -$307.8M | -$1.24B | -$29.7M |
| Capital Circulante | $496.4M | $1.69B | $772.8M | $4.77B | $652.3M | $2.97B | $271.8M | $1.23B | $27.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $11.56B | $30.1M | $191.1M | $190.6M |
| Activos Totales | $14.06B | $37.2M | $232.1M | $231.5M |
| Pasivos Totales | $937.5M | $4.2M | $30.5M | $30.4M |
| Patrimonio Neto | $13.12B | $33.0M | $201.6M | $201.1M |
| Deuda Total | $166.0M | $438458 | $4.5M | $4.5M |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$298.2M | -$402.8M | -$1.45B | $470.9M | -$2.33B | -$2.51B | -$208.2M | -$362.7M | -$88.3M |
| Amortizaciones | $1.6M | $6.7M | $15.6M | $23.1M | $34.1M | $63.8M | $1.1M | $7.1M | $856000 |
| Compensación en Acciones | $7.0M | $3.5M | $366.9M | $493.5M | $608.6M | $357.1M | $10.3M | -$14.2M | $6.0M |
| Cambio en Capital Circulante | $25.0M | $147.1M | $184.8M | -$240.6M | $394.5M | $552.1M | -$37.2M | -$20.5M | $17.1M |
| Flujo de Caja Operativo | -$252.2M | -$280.7M | -$868.0M | $433.6M | -$973.1M | -$1.10B | -$72.9M | -$384.4M | -$20.6M |
| Inversiones (CapEx) | -$20.3M | -$14.4M | -$12.2M | -$8.0M | -$29.9M | -$45.8M | -$164354 | -$350342 | -$7000 |
| Adquisiciones | $93.3M | 0 | -$224.7M | -$257.7M | -$6.0M | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | -$5.3M | 0 | -$3.1M | -$8.7M | -$2.4M | 0 |
| Dividendos Pagados | 0 | 0 | -$5.3M | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$272.5M | -$295.1M | -$880.2M | $425.6M | -$1.00B | -$1.15B | -$73.0M | -$384.8M | -$20.6M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | $13.1M | -$14.6M | -$16.5M | -$16.4M |
| Inversiones (CapEx) | $41 | 0 | -$494625 | -$493241 |
| Flujo de Caja Libre | $13.1M | -$14.6M | -$16.9M | -$16.9M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $10.4M | $3.9M | $3.4M | $3.4M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | +377.4% | -44.2% | +5042.2% | -94.3% | -112.2% | +141.9% | -100.0% | |
| Crecimiento Beneficio Neto (anual) | | -35.1% | -259.5% | +132.5% | -595.1% | +58.5% | -51.5% | +88.9% | +95.9% |
| Crecimiento BPA (anual) | | -34.9% | -268.9% | +131.6% | -480.4% | +1.0% | +42.0% | +74.7% | +96.4% |
| Cambio en Acciones (anual) | | +0.0% | +0.0% | +17.5% | +11.1% | +8.6% | +0.9% | -2.5% | -48.7% |
| Crecimiento FCF (anual) | | -8.3% | -198.3% | +148.3% | -335.7% | -14.5% | +93.6% | -427.0% | +94.6% |
| Margen Bruto | 102.6% | 100.0% | 100.0% | 100.0% | 47.3% | 100.0% | 100.0% | | |
| Margen Operativo | -2431.2% | -847.4% | -4883.2% | 10.1% | -2353.1% | 3422.2% | -11395.1% | | |
| Margen EBITDA | -2479.5% | -803.1% | -657.5% | 10.9% | -2337.4% | 3331.5% | -7674.2% | | |
| Margen Neto | -2647.4% | -749.0% | -4826.8% | 30.5% | -2648.7% | 9044.6% | -32674.0% | | |
| Margen FCF | -2418.8% | -548.7% | -2934.1% | 27.6% | -1139.5% | 10737.7% | -1627.8% | | |
| Tasa Impositiva Efectiva | -0.0% | -0.4% | -0.0% | 2.5% | 0.0% | 0.6% | 85.9% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-4.68 | $-5.07 | $-15.13 | $6.22 | $-13.20 | $-13.92 | $-0.88 | $-4.74 | $-0.49 |
| Dividendo por Acción | $0.00 | $0.00 | $0.09 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $58.2M | $58.2M | $58.2M | $68.2M | $75.9M | $82.5M | $83.2M | $81.2M | $41.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -1.45% |
| Rentabilidad sobre capital invertido | -29.03% |
| Rentabilidad sobre activos | -21.17% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.02 |
| Ratio corriente | 7.64 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -15.86 | -12.41 | -3.41 | 38.11 | -9.80 | -0.95 | -0.77 | -1.39 | -25.22 |
| P/VC | 11.53 | -5.23 | 4.73 | 3.73 | 31.95 | 0.79 | 4.62 | 0.34 | 5.02 |
| P/V | 419.96 | 92.96 | 168.74 | 13.61 | 259.67 | -222.39 | 250.09 | 0.00 | 0.00 |
| Margen Bruto | 102.6% | 100.0% | 100.0% | 100.0% | 47.3% | 100.0% | 100.0% | 0.0% | 0.0% |
| Margen Operativo | -2431.2% | -847.4% | -4883.2% | 10.1% | -2353.1% | 3422.2% | -11395.1% | 0.0% | 0.0% |
| Margen Neto | -2647.4% | -749.0% | -4826.8% | 30.5% | -2648.7% | 9044.6% | -32674.0% | 0.0% | 0.0% |